Prices are updated after-hours

Pharmaceuticals: major

Timber Pharmaceuticals, Inc.

TMBR | $0.3426 -2.69% 3K

(0.0% 1d) (0.0% 1m) (-75.9% 1y) (0.0% 2d) (0.0% 3d) (1.4% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 1,176,055
http://www.timberpharma.com/
Sec Filling | Patents | 3 employees

(US) Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, tuberous sclerosis complex and localized scleroderma. The company is headquartered in Woodcliff Lake, NJ.

sclerosis msa treatment

add to watch list Paper trade email alert is off

Acer Therapeutics Inc.

ACER | $0.9 -3.61% 420K

Health Technology

(0.0% 1d) (0.0% 1m) (3.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1077.06% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 22,017,353
http://www.acertx.com
Sec Filling | Patents | 17 employees

(US) Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.

acquisitions urine urea treatment

add to watch list Paper trade email alert is off

Adamis Pharmaceuticals Corporation

ADMP | $0.7751 0.86% 2.6% 120K

Health Technology

(0.0% 1d) (0.0% 1m) (-87.2% 1y) (0.0% 2d) (0.9% 3d) (0.0% 7d) (20.14% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 7,254,264
http://www.adamispharmaceuticals.com
Sec Filling | Patents | 171 employees

(US) Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.

respiratory opioid

add to watch list Paper trade email alert is off

Evelo Biosciences, Inc.

EVLO | $0.3165 -87.39% 710K

Health Technology

(0.0% 1d) (0.0% 1m) (-89.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-17.9% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 6,008,068
http://www.evelobio.com
Sec Filling | Patents | 98 employees

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

cancer msa treatment

add to watch list Paper trade email alert is off

Brickell Biotech, Inc.

BBI | $2.12 16.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-74.2% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 6,092,806
http://www.brickellbio.com
Sec Filling | Patents | 15 employees

(US) Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

dermatitis skin t-cell treatment ceiling

add to watch list Paper trade email alert is off

Allena Pharmaceuticals, Inc.

ALNA | $0.075 -12.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (431.58% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 9,156,242
http://www.allenapharma.com
Sec Filling | Patents | 83 employees

(United States) Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

kidney diseases kidney stones treatment kidney

add to watch list Paper trade email alert is off

Amryt Pharma plc

AMYT | News | $14.7 0.0% 2.4M

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 940,255,350
http://amrytpharma.com
Sec Filling | Patents | n/a employees

Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. It operates through the following segments: Commercial, Research and Development. The Commercial segment includes the financial results of the Group's two current commercial product lines, Imlan and Lojuxta. The Research and Development segment comprises the financial results of the Group’s two current research and development assets, AP101 and AP102. The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.

treatment

Drugs

Juxtapid (lomitapide mesylate)
Myalept (metreleptin)

add to watch list Paper trade email alert is off

Chinook Therapeutics, Inc.

KDNY | $40.39 0.22% -0.17% 0

Health Technology

(0.0% 1d) (0.0% 1m) (83.6% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (-30.62% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,900,203,021
http://www.chinooktx.com
Sec Filling | Patents | 96 employees

(US) Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

kidney diseases kidney

add to watch list Paper trade email alert is off

Codiak BioSciences, Inc.

CDAK | $0.057 -55.99% -131.25% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.9% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 2,099,289
http://www.codiakbio.com
Sec Filling | Patents | 105 employees

(United States) Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.

diagnostics

add to watch list Paper trade email alert is off

Athenex, Inc.

ATNX | $0.2031 -7.78% 1.9M

Health Technology

(0.0% 1d) (0.0% 1m) (-82.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees

(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

cancer tirbanibulin treatment

add to watch list Paper trade email alert is off

Ayala Pharmaceuticals, Inc.

AYLA | $0.5036 5.84% -0.7% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (15.3% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 7,463,718
http://www.ayalapharma.com
Sec Filling | Patents | 29 employees

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel.

cancer israel diagnostics

add to watch list Paper trade email alert is off

Baudax Bio, Inc.

BXRX | $0.1864 -54.35% 330K

Health Technology

(0.0% 1d) (0.0% 1m) (-91.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.34% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 1,710,656
http://www.baudaxbio.com
Sec Filling | Patents | 25 employees

Baudax Bio, Inc. is a pharmaceutical company focusing on developing and commercializing products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.

Drugs

Anjeso (meloxicam)

add to watch list Paper trade email alert is off

AgeX Therapeutics, Inc.

AGE A | $11.1 0.0% 3.8K

Health Technology

(0.0% 1d) (-11.9% 1m) (1607.7% 1y) (0.0% 2d) (2.2% 3d) (-11.9% 7d) (-14.98% volume)
Earnings Calendar:
Market Cap: $ 27,757,370
http://www.agexinc.com
Sec Filling | Patents | 17 employees

(US) AgeX Therapeutics, Inc. operates as a biotechnology company. The firm focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its technology platforms include PureStem, UniverCyte, iTR and HyStem. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.

msa

add to watch list Paper trade email alert is off

Forma Therapeutics Holdings, Inc.

FMTX | $20.01 -0.15%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 957,529,666
https://formatherapeutics.com
Sec Filling | Patents | 105 employees

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

cancer prostate cancer t-cell treatment ceiling

add to watch list Paper trade email alert is off

LogicBio Therapeutics, Inc.

LOGC | $2.07 -0.48%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-0.5% 7d) (NaN% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 68,232,857
http://www.logicbio.com
Sec Filling | Patents | 41 employees

(US) LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.

genomic genome editing

add to watch list Paper trade email alert is off

Orchard Therapeutics plc

ORTX | $16.7 0.0% 370K

Health Technology

(0.0% 1d) (0.0% 1m) (247.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 38,010,937
http://orchard-tx.com
Sec Filling | Patents | 252 employees

(United Kingdom) Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

gene therapies urea treatment

add to watch list Paper trade email alert is off

Oyster Point Pharma, Inc.

OYST | $11.17 0.18% -0.27%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (583.77% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 299,850,742
http://www.oysterpointrx.com
Sec Filling | Patents | 17 employees

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.

eye diseases eye ocular msa 3d

add to watch list Paper trade email alert is off

PhaseBio Pharmaceuticals, Inc.

PHAS | $0.0701 -23.97%

Health Technology

(0.0% 1d) (-8.1% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-8.1% 7d) (450.84% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 3,495,054
http://www.phasebio.com
Sec Filling | Patents | 40 employees

(US) PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

add to watch list Paper trade email alert is off

Provention Bio, Inc.

PRVB | $24.98 0.08% 9.1M

Health Technology

(0.0% 1d) (0.0% 1m) (2.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 2,367,626,233
http://www.proventionbio.com
Sec Filling | Patents | 19 employees

(US) Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.

diabetes diabetic treatment

add to watch list Paper trade email alert is off

Karuna Therapeutics, Inc.

KRTX | $329.83 0.0% 1.9M

Health Technology

(0.0% 1d) (0.0% 1m) (67.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (672.96% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 12,599,265,884
http://www.karunatx.com
Sec Filling | Patents | 19 employees

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders.The company was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.

nervous system msa schizophrenia

add to watch list Paper trade email alert is off